Tim Kutzkey Biography and Net Worth

Director of Surrozen

Dr. Kutzkey previously served on Surrozen’s Board from April 2016 until June 2024, as well as having served as the Company’s interim Chief Executive Officer from inception to April 2018. Dr. Kutzkey brings extensive business leadership experience across a broad range of roles and currently serves as Managing Partner of The Column Group, LLC, a venture capital partnership, where he has served in various roles since 2007. Prior to The Column Group, Dr. Kutzkey served as a scientist at Kai Pharmaceuticals, Inc. Dr. Kutzkey also serves on the board of directors for several privately-held biotechnology companies. Dr. Kutzkey obtained a Ph.D. in molecular and cell biology from the University of California, Berkely and completed his undergraduate degree in biological sciences from Stanford University.

What is Tim Kutzkey's net worth?: The estimated net worth of Tim Kutzkey is at least $33.59 million as of January 15th, 2026. Dr. Kutzkey owns 1,005,732 shares of Surrozen stock worth more than $33,591,449 as of April 30th. This net worth evaluation does not reflect any other assets that Dr. Kutzkey may own. Learn More about Tim Kutzkey's net worth.
How do I contact Tim Kutzkey?: The corporate mailing address for Dr. Kutzkey and other Surrozen executives is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. Surrozen can also be reached via phone at 650-489-9000 and via email at [email protected]. Learn More on Tim Kutzkey's contact information.
Has Tim Kutzkey been buying or selling shares of Surrozen?: Tim Kutzkey has not been actively trading shares of Surrozen within the last three months. Most recently, on Tuesday, January 20th, Tim Kutzkey bought 18,052 shares of Surrozen stock. The stock was acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the transaction, the director now directly owns 1,016,658 shares of the company's stock, valued at $19,926,496.80. Learn More on Tim Kutzkey's trading history.
Who are Surrozen's active insiders?: Surrozen's insider roster includes Tim Kutzkey (Director), Yang Li (VP), and Charles Williams (COO). Learn More on Surrozen's active insiders.
Are insiders buying or selling shares of Surrozen?: During the last year, Surrozen insiders bought shares 28 times. They purchased a total of 1,033,505 shares worth more than $16,849,523.68. During the last year, insiders at the sold shares 2 times. They sold a total of 2,684 shares worth more than $53,331.08. The most recent insider tranaction occured on March, 24th when Major Shareholder Tcg Crossover Gp Ii, Llc bought 106,658 shares worth more than $2,633,386.02. Insiders at Surrozen own 31.7% of the company. Learn More about insider trades at Surrozen.
Information on this page was last updated on 3/24/2026.

Tim Kutzkey Insider Trading History at Surrozen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/20/2026	Buy	18,052	$19.60	$353,819.20	1,016,658
1/16/2026	Buy	2,562	$20.00	$51,240.00	1,007,090
1/15/2026	Buy	11,893	$19.89	$236,551.77	1,005,732
1/14/2026	Buy	5,523	$19.99	$110,404.77	999,429
1/13/2026	Buy	12,470	$19.80	$246,906.00	996,502
1/6/2026	Buy	15,100	$19.89	$300,339.00	989,893
12/5/2025	Buy	30,884	$19.54	$603,473.36	981,890
12/4/2025	Buy	5,266	$17.35	$91,365.10	965,509
11/13/2025	Buy	315,457	$12.65	$3,990,531.05	962,718
4/4/2024	Buy	193,548	$15.50	$2,999,994.00	332,885

Tim Kutzkey Buying and Selling Activity at Surrozen

Surrozen Company Overview

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Today's Range

Now: $33.40

$30.79

$33.60

50 Day Range

MA: $28.02

$25.00

$33.03

2 Week Range

Now: $33.40

$5.90

$33.96

Volume

81,946 shs

Average Volume

113,538 shs

Market Capitalization

$383.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52